Xanomeline, an M(1)/M(4) preferring muscarinic cholinergic receptor agonist, produces antipsychotic-like activity in rats and mice.

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Schizophrenia Research

• Publication date

  2000-05-05

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0920-9964(99)00138-3PMID 10785583
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pharmacological specificity of conditioned avoidance response inhibition in rats: inhibition by neuroleptics and correlation to dopamine receptor blockade.

  2009cited by this paper
• Seroquel: electrophysiological profile of a potential atypical antipsychotic

  2005cited by this paper
• Inhibition of SKF 38393- and pergolide-induced circling in rats with unilateral 6-OHDA lesion is correlated to dopamine D-1 and D-2 receptor affinitiesin vitro

  2005cited by this paper
• Muscarinic receptor agonists, like dopamine receptor antagonist antipsychotics, inhibit conditioned avoidance response in rats.

  1999cited by this paper
• A randomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer's disease.

  1998cited by this paper
• Muscarinic agonists exhibit functional dopamine antagonism in unilaterally 6-OHDA lesioned rats.

  1998cited by this paper
• Unexpected antipsychotic-like activity with the muscarinic receptor ligand (5R,6R)6-(3-propylthio-1,2,5-thiadiazol-4-yl)-1-azabicyclo[3.2.1]octane .

  1998cited by this paper
• Olanzapine increases in vivo dopamine and norepinephrine release in rat prefrontal cortex, nucleus accumbens and striatum

  1998cited by this paper
• Activation of midbrain presumed dopaminergic neurones by muscarinic cholinergic receptors: an in vivo electrophysiological study in the rat

  1998cited by this paper
• Xanomeline: A selective muscarinic agonist for the treatment of Alzheimer's disease

  1997cited by this paper
• Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease.

  1997cited by this paper
• Modulation of apomorphine-induced rotations in unilaterally 6-hydroxydopamine lesioned rats by cholinergic agonists and antagonists.

  1997cited by this paper
• Effect of Tacrine on Behavioral Symptoms in Alzheimer's Disease: An Open-Label Study

  1996cited by this paper
• Electrophysiological Effects of Olanzapine, a Novel Atypical Antipsychotic, on A9 and A10 Dopamine Neurons

  1996cited by this paper
• Muscarinic agonist inhibition of rat striatal adenylate cyclase is enhanced by dopamine stimulation.

  1996cited by this paper
• Schizophrenia and Alzheimer's disease: clinical and pathophysiologic analogies.

  1996cited by this paper
• Antagonism of striatal muscarinic receptors inhibiting dopamine D1 receptor‐stimulated adenylyl cyclase activity by cholinoceptor antagonists used to treat Parkinson's disease

  1996cited by this paper
• Schizophrenia research moves to the prefrontal cortex.

  1994cited by this paper
• Xanomeline: a novel muscarinic receptor agonist with functional selectivity for M1 receptors.

  1994cited by this paper
• Differential Effects of Locally Administered Clozapine and Haloperidol on Dopamine Efflux in the Rat Prefrontal Cortex and Caudate‐Putamen

  1994cited by this paper
• Neurochemical effects of the M1 muscarinic agonist xanomeline (LY246708/NNC11-0232).

  1994cited by this paper
• Cholinergic therapy of behavioral disturbances in Alzheimer's disease

  1993cited by this paper
• Blockade of muscarinic receptors potentiates D1 dependent turning behavior and c-fos expression in 6-hydroxydopamine-lesioned rats but does not influence D2 mediated responses.

  1993cited by this paper
• Physostigmine ameliorates the delusions of Alzheimer's disease.

  1993cited by this paper
• Phenotypical characterization of the rat striatal neurons expressing muscarinic receptor genes

  1992cited by this paper
• The regulation of subcortical dopamine systems by the prefrontal cortex: interactions of central dopamine systems and the pathogenesis of schizophrenia.

  1992cited by this paper
• The behavioral pharmacology of olanzapine, a novel "atypical" antipsychotic agent.

  1992cited by this paper
• Cholinergic modulation of [3H]dopamine release from dendrosomes of rat substantia nigra

  1991cited by this paper
• Utilization of microdialysis for assessing the release of mesotelencephalic dopamine following clozapine and other antipsychotic drugs.

  1990cited by this paper
• A Metaanalysis of Controlled Trials of Neuroleptic Treatment in Dementia

  1990cited by this paper
• Differential effects of classical and atypical antipsychotic drugs on A9 and A10 dopamine neurons.

  1983cited by this paper
• Muscarinic Receptors Modulate Dopamine‐Activated Adenylate Cyclase of Rat Striatum

  1983cited by this paper
• The mesolimbic nucleus accumbens is critically involved with the mediation of the motor inhibitory and facilitatory effects of dopamine agonists on mouse spontaneous climbing behaviour.

  1983cited by this paper
• The mesolimbic system, denervation and the climbing response in the mouse.

  1980cited by this paper
• Acute and chronic haloperidol treatment: comparison of effects on nigral dopaminergic cell activity.

  1978cited by this paper
• Climbing behaviour induced by apomorphine in mice: a potential model for the detection of neuroleptic activity.

  1978cited by this paper
• Pharmacological investigations of the cholinergic imbalance hypotheses of movement disorders and psychosis.

  1978cited by this paper
• Effects of various drugs on escape and avoidance behavior.

  1958cited by this paper

• Targeting muscarinic receptors for treating schizophrenia.

  2026cites this paper
• Novel opportunities for treating complex neuropsychiatric and neurocognitive conditions based on recent developments with xanomeline

  2025cites this paper
• Xanomeline and Trospium Chloride Versus Placebo for the Treatment of Schizophrenia: A Post Hoc Analysis of Number Needed to Treat, Number Needed to Harm, and Likelihood to Be Helped or Harmed

  2025cites this paper
• From theory to therapy: unlocking the potential of muscarinic receptor activation in schizophrenia with the dual M1/M4 muscarinic receptor agonist xanomeline and trospium chloride and insights from clinical trials

  2025cites this paper
• Pharmacological reduction of reverse-translated hippocampal hyperactivity in mouse: relevance for psychosis

  2025cites this paper
• Pharmacological Interventions for Negative Symptoms in Schizophrenia: A Systematic Review of Randomised Control Trials

  2025cites this paper
• The role of rodent behavioral models of schizophrenia in the ongoing search for novel antipsychotics

  2025cites this paper
• Impact of selected second and third generation antipsychotics on cognitive dysfunction in schizophrenia-spectrum disorders. Systematic review and network meta-analysis.

  2025cites this paper
• Exploration of current situation of psychotropic drugs research and development in China based on drug clinical trials

  2025cites this paper
• Xanomeline-Trospium for the Treatment of Schizophrenia.

  2025cites this paper
• Xanomeline/Trospium (Cobenfy): A Novel Approach for the Treatment of Schizophrenia in Adults.

  2025cites this paper
• Targeting muscarinic receptors in schizophrenia treatment: Novel antipsychotic xanomeline/trospium chloride

  2025cites this paper
• Preclinical efficacy of the muscarinic agonist ML-007 in psychosis models depends on both M1 and M4 receptors.

  2025cites this paper
• The potential of muscarinic M1 and M4 receptor activators for the treatment of cognitive impairment associated with schizophrenia

  2024cites this paper
• Ligand bias at the muscarinic acetylcholine receptor family: opportunities and challenges.

  2024cites this paper
• Current Findings and Potential Mechanisms of KarXT (Xanomeline–Trospium) in Schizophrenia Treatment

  2024cites this paper
• Normative modelling of molecular-based functional circuits captures clinical heterogeneity transdiagnostically in psychiatric patients

  2024cites this paper
• Bridging cholinergic signalling and inflammation in schizophrenia

  2024cites this paper
• Beyond dopamine: Novel strategies for schizophrenia treatment

  2024cites this paper
• Muscarinic Receptor Activators as Novel Treatments for Schizophrenia.

  2024cites this paper
• The Impact of Xanomeline and Trospium Chloride on Cognitive Impairment in Acute Schizophrenia: Replication in Pooled Data From Two Phase 3 Trials.

  2024cites this paper
• IUPHAR Review on muscarinic M1 and M4 receptors as drug treatment targets relevant to the molecular pathology of schizophrenia.

  2024cites this paper
• Efficacy of KarXT on negative symptoms in acute schizophrenia: A post hoc analysis of pooled data from 3 trials.

  2024cites this paper
• Emerging trends in antipsychotic and antidepressant drug development: Targeting nonmonoamine receptors and innovative mechanisms

  2023cites this paper
• Informing individualized multi-scale neural signatures of clozapine response in patients with treatment-refractory schizophrenia

  2023cites this paper
• Canonical and Non-Canonical Antipsychotics’ Dopamine-Related Mechanisms of Present and Next Generation Molecules: A Systematic Review on Translational Highlights for Treatment Response and Treatment-Resistant Schizophrenia

  2023cites this paper
• Cross-diagnostic determinants of cognitive functioning: the muscarinic cholinergic receptor as a model system

  2023cites this paper
• Targeting muscarinic receptors for the treatment of alcohol use disorders: Opportunities and hurdles for clinical development

  2023cites this paper
• Increased Metabolic Potential, Efficacy, and Safety of Emerging Treatments in Schizophrenia

  2023cites this paper
• Targeting the Actions of Muscarinic Receptors on Dopamine Systems: New Strategies for Treating Neuropsychiatric Disorders.

  2023cites this paper
• Más allá de lo habitual: Nuevos enfoques en la terapia de la esquizofrenia resistente

  2023cites this paper
• Muscarinic M1 and M4 receptor agonists for schizophrenia: promising candidates for the therapeutic arsenal

  2023cites this paper
• Normative Modelling of Molecular-based Functional Neurocircuits Captures Clinical Heterogeneity Transdiagnostically in Neuropsychiatric Patients

  2023cites this paper
• Risperidone on apomorphine-induced stereotyped behavior and auditory sensory gating in rhesus monkeys.

  2022cites this paper
• Modulation of Muscarinic Signalling in the Central Nervous System by Steroid Hormones and Neurosteroids

  2022cites this paper
• Muscarinic acetylcholine receptors for psychotic disorders: bench-side to clinic.

  2022cites this paper
• Muscarinic Acetylcholine Receptor Agonists as Novel Treatments for Schizophrenia.

  2022cites this paper
• Clozapine's multiple cellular mechanisms: What do we know after more than fifty years? A systematic review and critical assessment of translational mechanisms relevant for innovative strategies in treatment-resistant schizophrenia.

  2022cites this paper
• Functionally selective and biased agonists of muscarinic receptors.

  2021cites this paper
• New Antipsychotic Medications in the Last Decade

  2021cites this paper
• Beyond Dopamine Receptor Antagonism: New Targets for Schizophrenia Treatment and Prevention

  2021cites this paper
• A review on emerging drug targets in treatment of schizophrenia.

  2020cites this paper
• Muscarinic M1 and M4 receptors: Hypothesis driven drug development for schizophrenia.

  2020cites this paper
• The M1/M4 agonist xanomeline modulates functional connectivity and NMDAR antagonist-induced changes in the mouse brain

  2020cites this paper
• Profiling of behavioral effects evoked by ketamine and the role of 5HT2 and D2 receptors in ketamine-induced locomotor sensitization in mice.

  2020cites this paper
• The M1/M4 preferring muscarinic agonist xanomeline modulates functional connectivity and NMDAR antagonist-induced changes in the mouse brain

  2020cites this paper
• In Vivo Pharmacological Comparison of TAK-071, a Positive Allosteric Modulator of Muscarinic M1 Receptor, and Xanomeline, an Agonist of Muscarinic M1/M4 Receptor, in Rodents.

  2019cites this paper
• Roles of the M4 acetylcholine receptor in the basal ganglia and the treatment of movement disorders

  2019cites this paper
• The role of dopamine D1‐ and D2‐like receptors related to muscarinic M1 receptors in impulsive choice in high‐impulsive and low‐impulsive rats

  2019cites this paper
• Activation of the mGlu1 metabotropic glutamate receptor has antipsychotic-like effects and is required for efficacy of M4 muscarinic receptor allosteric modulators

  2018cites this paper
• Discovery and Development of Muscarinic Acetylcholine M4 Activators as Promising Therapeutic Agents for CNS Diseases.

  2018cites this paper
• Classics in Chemical Neuroscience: Xanomeline.

  2017cites this paper
• Positive allosteric modulation of M1 and M4 muscarinic receptors as potential therapeutic treatments for schizophrenia

  2017cites this paper
• Identification and in vivo Characterization of a Potential TAAR1 Antagonist

  2017cites this paper
• Broad analgesic activity of a novel, selective M1 agonist

  2017cites this paper
• M1 muscarinic allosteric modulators slow prion neurodegeneration and restore memory loss

  2016cites this paper
• Molecular Mechanisms of Action of M5 Muscarinic Acetylcholine Receptor Allosteric Modulators

  2016cites this paper
• Ameliorative effects of amide derivatives of 1,3,4-thiadiazoles on scopolamine induced cognitive dysfunction.

  2016cites this paper
• An Antibody Biosensor Establishes the Activation of the M1 Muscarinic Acetylcholine Receptor during Learning and Memory*♦

  2016cites this paper
• Alpha7 nicotinic acetylcholine receptor agonists and PAMs as adjunctive treatment in schizophrenia. An experimental study.

  2016cites this paper
• Aufmerksamkeits- und Arbeitsgedächtnisleistung nikotinabhängiger paranoid-schizophrener Patienten unter dem Einfluss von Nikotinkarenz bzw. -zufuhr sowie in Abhängigkeit der Affinität ihres Atypischen Antipsychotikums zum muskarinergen M1-Rezeptor

  2015cites this paper
• Antipsychotic-Like Effect of the Muscarinic Acetylcholine Receptor Agonist BuTAC in Non-Human Primates

  2015cites this paper
• The muscarinic system, cognition and schizophrenia.

  2015cites this paper
• Predictive validity of a MK-801-induced cognitive impairment model in mice: implications on the potential limitations and challenges of modeling cognitive impairment associated with schizophrenia preclinically.

  2014cites this paper
• Long-Term Activation upon Brief Exposure to Xanomleline Is Unique to M1 and M4 Subtypes of Muscarinic Acetylcholine Receptors

  2014influential citation
• Selective Activation of M4 Muscarinic Acetylcholine Receptors Reverses MK-801-Induced Behavioral Impairments and Enhances Associative Learning in Rodents

  2014cites this paper
• Animal Models of Psychosis: Current State and Future Directions

  2014cites this paper
• Antipsychotic Drug-Like Effects of the Selective M4 Muscarinic Acetylcholine Receptor Positive Allosteric Modulator VU0152100

  2014cites this paper
• Muscarinic Acetylcholine Receptor Activators

  2014cites this paper
• [11C]AF150(S), an agonist PET ligand for M1 muscarinic acetylcholine receptors

  2013cites this paper
• Development of M1 mAChR allosteric and bitopic ligands: prospective therapeutics for the treatment of cognitive deficits.

  2013cites this paper
• Modulowanie funkcji układu cholinergicznego w leczeniu schizofrenii – dziś i jutro

  2013cites this paper
• Allosteric modulation of the M 1 muscarinic acetylcholine receptor : improving cognition and a potential treatment for schizophrenia and Alzheimer ’ s disease

  2013cites this paper
• The Muscarinic Acetylcholine Receptor Agonist BuTAC Mediates Antipsychotic-Like Effects via the M4 Subtype

  2013cites this paper
• Acute and chronic effects of the M1/M4-preferring muscarinic agonist xanomeline on cocaine vs. food choice in rats

  2013cites this paper
• Classics in chemical neuroscience: clozapine.

  2013cites this paper
• Allosteric modulation of the M1 muscarinic acetylcholine receptor: improving cognition and a potential treatment for schizophrenia and Alzheimer's disease.

  2013cites this paper
• Utility of Combined Treatment with Antipsychotic and Antidepressant Drugs: Scientific Rationales and Clinical Implications

  2013cites this paper
• Cholinergic muscarinic M4 receptor gene polymorphisms: a potential risk factor and pharmacogenomic marker for schizophrenia.

  2013cites this paper
• On the role of forebrain cholinergic innervation for phencyclidine-induced behaviors and gene expression patterns

  2013cites this paper
• An allosteric enhancer of M4 muscarinic acetylcholine receptor function inhibits behavioral and neurochemical effects of cocaine

  2012cites this paper
• Distinct muscarinic acetylcholine receptor subtypes mediate pre- and postsynaptic effects in rat neocortex

  2012cites this paper
• Muscarinic acetylcholine receptor-mediated effects in slices from human epileptogenic cortex.

  2012cites this paper
• Muscarinic and Nicotinic Acetylcholine Receptor Agonists and Allosteric Modulators for the Treatment of Schizophrenia

  2012cites this paper
• Metabotropic Glutamate 2/3 Receptor Agonists and Positive Allosteric Modulators of Metabotropic Glutamate Receptor 2 as Novel Agents for the Treatment of Schizophrenia

  2012cites this paper
• Radiosynthesis and biological evaluation of the M1 muscarinic acetylcholine receptor agonist ligand [11C]AF150(S)

  2012cites this paper
• Muscarinic Acetylcholine Receptors as Novel Targets for the Development of Therapeutics for Schizophrenia

  2012cites this paper
• Novel Allosteric Agonists of M1 Muscarinic Acetylcholine Receptors Induce Brain Region-Specific Responses That Correspond with Behavioral Effects in Animal Models

  2012cites this paper
• Xanomeline Modulation of the Blood Oxygenation Level-Dependent Signal in Awake Rats: Development of Pharmacological Magnetic Resonance Imaging as a Translatable Pharmacodynamic Biomarker for Central Activity and Dose Selection

  2012cites this paper
• Selective activation of muscarinic acetylcholine receptors for the treatment of schizophrenia.

  2012cites this paper
• Muscarinic agonists and antagonists in schizophrenia: recent therapeutic advances and future directions.

  2012cites this paper
• Muscarinic Acetylcholine Receptor Subtypes as Potential Drug Targets for the Treatment of Schizophrenia, Drug Abuse and Parkinson's Disease.

  2012cites this paper
• Muscarinic antagonist control of myopia: evidence for M4 and M1 receptor-based pathways in the inhibition of experimentally-induced axial myopia in the tree shrew.

  2012cites this paper
• Muscarinic mechanisms in psychotic disorders.

  2012cites this paper
• Potential action of betel alkaloids on positive and negative symptoms of schizophrenia: A review

  2012cites this paper
• The M₁/M₄ preferring agonist xanomeline reverses amphetamine-, MK801- and scopolamine-induced abnormalities of latent inhibition: putative efficacy against positive, negative and cognitive symptoms in schizophrenia.

  2011cites this paper
• Involvement of a Subpopulation of Neuronal M4 Muscarinic Acetylcholine Receptors in the Antipsychotic-like Effects of the M1/M4 Preferring Muscarinic Receptor Agonist Xanomeline

  2011influential citation
• Impact of species variability and ‘probe‐dependence’ on the detection and in vivo validation of allosteric modulation at the M4 muscarinic acetylcholine receptor

  2011cites this paper
• The effectiveness of multi-target agents in schizophrenia and mood disorders: Relevance of receptor signature to clinical action.

  2010cites this paper
• Cognitive effects of muscarinic M1 functional agonists in non-human primates and clinical trials.

  2010cites this paper